Anaplastic Thyroid Cancer (ATC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Anaplastic Thyroid Cancer (ATC) Market Outlook

Thelansis’s “Anaplastic Thyroid Cancer (ATC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Anaplastic Thyroid Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Anaplastic Thyroid Cancer (ATC) Overview

Anaplastic thyroid carcinoma (ATC), also referred to as undifferentiated carcinoma, is a rare and highly aggressive malignant tumor, constituting approximately 2% to 3% of all thyroid gland neoplasms. ATC is one of the most lethal diseases globally and is associated with a very poor prognosis. It is characterized by significant local invasion and frequently presents with metastatic spread to regional lymph nodes and distant sites. ATC risk factors include low educational level, type B blood group and goiter. Patients with poorly differentiated thyroid cancer exhibiting specific characteristics tend to present with more complicated and adverse clinicopathological findings, including older age, male gender, advanced locoregional disease, and distant metastases. Approximately 20% of patients with ATC have a history of differentiated thyroid cancer, and up to 30% of ATC cases may have associated synchronous differentiated cancer. The majority of these synchronous thyroid tumors are papillary carcinomas, although follicular types have also been reported. The transformation from differentiated to anaplastic carcinoma has been documented, with Tp53 gene inactivation playing a significant role in this progression. Thyroid-specific rearrangements such as RET/PTC and PAX8/PPARγ are rarely found in poorly differentiated or undifferentiated thyroid cancer, indicating that these genetic alterations do not predispose cells to dedifferentiation. The histological differential diagnosis for ATC includes:

• Metastatic disease to the thyroid (e.g., metastatic clear-cell renal carcinoma)
• Primary thyroid lymphoma
• Primary thyroid sarcoma
• Poorly differentiated thyroid carcinoma
• Squamous cell thyroid carcinoma
• Medullary carcinoma

The recommended treatment for anaplastic thyroid carcinoma typically involves surgery, when feasible, accompanied by chemoradiation either concurrently or sequentially. However, most cases of ATC are unresectable at presentation due to the invasion of cervical structures, and surgery primarily aims to secure the patient’s airway. Anaplastic thyroid carcinoma is generally poorly responsive to any multimodal therapy.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: